Cockrell Group
Long only, deep value, value, growth at reasonable price

Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook

We are remaining positive on the outlook of Supernus Pharmaceuticals' (NASDAQ:SUPN) shares after the Company released its 4Q13 and FY2013 results. Reported revenues for 2013 were approximately $12 million, which exceeded analyst estimates of $8.3 million. Shares of the company closed up 2.62% at $9.15 on March 12, 2014 on news about the potential of the company's marketed products.

(click to enlarge)

Supernus is a Rockville, Maryland-based specialty pharmaceutical company that is focused on the development and commercialization of products for the treatment of central nervous system diseases. The company has recently seen the launch of two products for the treatment of epilepsy, Oxtellar XR™ and Trokendi XR™, and has experienced solid adoption in the marketplace. In the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details